UHUli S. Herrmann

Uli S. Herrmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uli S. Herrmann has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Akif Yeşilipek

    25Department of Pediatric Hematology and Oncology, Clinic Medical Park Antalya Hospital, Antalya, Turkey

    1 shared publication
  • Alexandra L. Laberko

    The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation; I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation

    1 shared publication
  • Andreas H. Groll

    Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children’s Hospital Münster, Münster, Germany

    1 shared publication
  • Andrew R. Gennery

    Institute of Cellular Medicine, Child Health, University of Newcastle upon Tyne, Newcastle Upon Tyne, United Kingdom

    1 shared publication
  • Anneke Hertig-Godeschalk

    Swiss Paraplegic Research

    1 shared publication
  • Annelies Santschi

    Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

    1 shared publication

Latest Publications

  • Open Access

    Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study

    by Uli S. Herrmann, Matthias Felber, Austen Worth, Sule Haskologlu, Figen Dogu, Victor A. Lewis, Brigitte Strahm, Andreas Groll, Andrew R. Gennery, Fabian Hauck, et al.

    Purine nucleoside phosphorylase (PNP) deficiency causes inadequate purine metabolite detoxification, which leads to combined immunodeficiency and variable neurologic symptoms. Hematopoietic stem cell transplantation (HSCT) cures the immunodeficiency, but large studies on the long-term outcomes are lacking. In a retrospective study of the European Society for Blood and Marrow Transplantation, we investigated 46 patients with PNP deficiency from 21 centers. We analyzed the presenting clinical signs and outcomes after HSCT. Cognition (0-3), hearing (0-3), interaction (0-4), movement (0-4), and occupation (0-3) (CHIMO) were scored at the last follow-up (FU) visit (no impairment, 17; mild, 15-16; moderate, 12-14; and severe impairment, 50%-100%)/low-level donor chimerism (11%-50%) was observed in 85%/15% of patients, respectively, leading to resolution of T lymphopenia. The median overall CHIMO score was 14 (6-17), while the median scores for each component were 3 (0-3), 3 (1-3), 4 (1-4), 3 (1-4), and 2 (0-3), respectively. Patients who underwent HSCT before 24 months after the initial presentation demonstrated superior OS (P = .049). Neurological symptoms that occurred before 11 months of age were associated with reduced OS (P = .027). While the overall results were satisfactory, earlier diagnosis could further improve outcomes.


  • Open Access

    Eyelid Closure Behavior of Patients with Idiopathic and Nonorganic Hypersomnia, Narcolepsy-Cataplexy, and Healthy Controls in the Maintenance of Wakefulness Test

    by Annelies Santschi, David R Schreier, Anneke Hertig-Godeschalk, Samuel Ej Knobel, Uli S Herrmann, Jelena Skorucak, Wolfgang J Schmitt, Johannes Mathis

    Purpose: Differential diagnosis of central disorders of hypersomnolence remains challenging, particularly between idiopathic (IH) and nonorganic hypersomnia (NOH). We hypothesized that eyelid closure behavior in the maintenance of wakefulness test (MWT) could be a valuable biomarker. Patients and Methods: MWT recordings of patients with IH, NOH, narcolepsy-cataplexy (NC), and healthy sleep-deprived controls (H) were retrospectively analyzed (15 individuals per group). For each MWT trial, visual scoring of face videography for partial (50– 80%) and full eyelid closure (≥ 80%) was performed from “lights off” to the first microsleep episode (≥ 3 s). Results: In all groups, the frequency and cumulative duration of periods with partial and full eyelid closure gradually increased toward the first microsleep episode. On the group level, significant differences occurred for the latency to the first microsleep episode (IH 21 min (18– 33), NOH 23 min (17– 35), NC 11 min (7– 19), H 10 min (6– 25); p = 0.009), the ratio between partial and full eyelid closure duration (IH 2.2 (0.9– 3.1), NOH 0.5 (0– 1.2), NC 2.8 (1.1– 5), H 0.7 (0.4– 3.3); p = 0.004), and the difference between full and partial eyelid closure duration in the five minutes prior to the first microsleep episode (∆full – partial eyelid closure duration: IH − 16 s (− 35 to 28); NOH 46 s (9– 82); NC − 6 s (− 26 to 5); H 10 s (− 4 to 18); p = 0.007). IH and NOH significantly differed comparing the ratio between partial and full eyelid closure (p = 0.005) and the difference between ∆full – partial eyelid closure duration in the five minutes prior to the first microsleep episode (p = 0.006). Conclusion: In the MWT, eyelid closure behavior (∆full – partial) in the period prior to the first microsleep episode could be of value for discriminating NOH from other etiologies of excessive daytime sleepiness, particularly IH.